PhRMA praises progress in US-China trade talks

As the Office of the US Trade Representative (USTR) prepares its annual “Special 301 Report,” the US pharmaceutical industry has submitted comments calling for an end to market access barriers globally.

Mandated by law, the USTR’s report is the outcome of a yearly review of the state of intellectual property rights protections and enforcement in countries around the world.

Leading American trade group Pharmaceutical Research and Manufacturers of America (PhRMA) called on the White House to “defend American biopharmaceutical innovators and jobs by ending market access and intellectual property barriers.”